कृपया अन्य खोज का प्रयास करें
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Charles L. Pope | 72 | 2010 | Executive Chairman |
Frederick W. Telling | 72 | 2010 | Independent Director |
Robert Clayton Koski | 65 | 2009 | Independent Director |
Kimberly M. Murphy | 60 | 2020 | Director |
Timothy Cooke | - | - | Member of Scientific Advisor |
Alan W. Dunton | 70 | 2011 | Independent Director |
David Zarley | - | - | Member of Scientific Advisor |
Terrence Cochrane | - | - | Member of Scientific Advisor |
John P. Gandolfo | 63 | 2023 | Independent Director |
Bruce A. Cassidy | 73 | 2023 | Independent Director |
James P. Kelly | - | 2024 | Chief Medical Officer & Member of Scientific Advisor |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है